ReviewApoptosis : an international journal on programmed cell death2026
The cGAS-STING pathway in fibroblast microenvironment: from molecular mechanisms to targeted therapies.
Review in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- cGAS-STING signaling in aging and age-related diseases: therapeutic promise and precaution.Archives of pharmacal research · 2026Review
- Metabolic regulation of macrophage polarization in myocardial infarction: from mechanisms to targeted therapies.Journal of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway serves as a core signaling axis for sensing cytosolic DNA and activating innate immunity. By recognizing abnormal DNA released from pathogens or tissue damage, it triggers the expression of type I interferons (IFN-I) and inflammatory cytokines, playing a pivotal role in innate immune defense, tumor immune surveillance, and tissue homeostasis regulation. As an important signaling hub in the fibroblast microenvironment, this pathway is involved in various pathophysiological processes such as antiviral immune responses, fibrosis progression, and remodeling of the tumor microenvironment (TME). In recent years, its potential in targeted therapy has become increasingly prominent: agonists of the pathway can enhance anti‑tumor immune responses, while inhibitors hold promise for alleviating aberrant inflammatory responses in fibrotic and autoimmune diseases. This review introduces the structural composition, signaling transduction process, and biological functions of the cGAS-STING pathway, and provides an overview of current research advances on related diseases, demonstrating the great potential of targeting this pathway in disease treatment.
Indexed as
Identifiers
41571936What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.